Clinical Trial Reveals Weekly Buprenorphine Injections Significantly Outperform Daily Sublingual Doses for Pregnant Patients Seeking Opioid Abstinence

Weekly buprenorphine injections found more effective than daily doses for opioid abstinence during pregnancy, according to a new NIH-supported clinical trial.

By: AXL Media

Published: Mar 17, 2026, 5:53 AM EDT

Source: Information for this report was sourced from National Institutes of Health (NIH)

A Breakthrough in Gestational Addiction Recovery

The landscape of treating opioid use disorder during pregnancy is shifting toward long-acting solutions that offer more stability than traditional daily regimens. A clinical trial supported by the National Institutes of Health has demonstrated that weekly injectable extended-release buprenorphine leads to higher rates of abstinence from illicit opioids when compared to sublingual administration. This development is particularly significant as healthcare providers seek more reliable ways to manage addiction in expectant mothers, who face unique physiological and psychological hurdles during the recovery process.

Addressing the Limitations of Traditional Sublingual Dosing

Standard treatments involving daily tablets or films placed under the tongue often suffer from fluctuating blood levels, which can trigger cravings and withdrawal symptoms between doses. According to Nora D. Volkow, M.D., director of the National Institute on Drug Abuse, these "peak-trough effects" frequently result in poor adherence and a higher risk of relapse. By moving to a subcutaneous injection, the study suggests that patients can achieve more consistent medication levels, thereby mitigating the physiological triggers that lead to continued illicit opioid use during critical stages of fetal development.

Quantifying Clinical Success and Patient Safety

In a multicenter trial involving 140 pregnant adults, researchers compared the efficacy of extended-release injections against sublingual buprenorphine with or without naloxone. The results, published in JAMA Internal Medicine, showed that illicit opioid abstinence was significantly higher in the group receiving weekly injections throughout their pregnancy. Furthermore, the data indicated that serious maternal adverse events were less frequent in the extended-release group, providing a strong argument for the safety profile of this formulation for both the mother and the developing child.